Comparative Pharmacology
Head-to-head clinical analysis: CARBATROL versus FELBATOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARBATROL versus FELBATOL.
CARBATROL vs FELBATOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Stabilizes neuronal membranes by blocking voltage-gated sodium channels, inhibiting repetitive firing of action potentials. Also enhances GABAergic activity.
Felbamate is a GABA receptor agonist and modulates NMDA receptor activity, though its exact mechanism is not fully understood. It appears to enhance GABA-mediated inhibition and inhibit voltage-gated sodium channels, reducing neuronal excitability.
Initial dose 200 mg orally twice daily, increase by 200 mg/day at weekly intervals; maintenance 800-1200 mg/day in 2 divided doses extended-release capsules.
1200-3600 mg/day orally in 3-4 divided doses; initial titration recommended.
None Documented
None Documented
Terminal elimination half-life 25-65 hours initially, then 12-17 hours after autoinduction; clinical context: requires dose adjustment after 3-5 weeks.
20-23 hours; steady state reached within 3-5 days; may be prolonged in hepatic impairment.
Renal: 70% as metabolites (including carbamazepine-10,11-epoxide) and 2-3% as unchanged drug; biliary/fecal: 30%.
Renal: 40-50% unchanged; Hepatic metabolism accounts for ~50% with glucuronidation and oxidation; minimal biliary/fecal excretion (<5%).
Category C
Category C
Anticonvulsant
Anticonvulsant